Abstract 99P
Background
In the era of immunotherapy, whether removal of tumor -draining lymph nodes (TDLNs) should be removed as the traditional surgery way or should be surgical method or preserved preservation remains controversialis still unknown.
Methods
In this study, 42 mismatch repair deficient (dMMR) and 42 mismatch repairs proficient (pMMR) colon cancer patients were enrolled. Imaging data and single-cell RNA sequencing of tumor-draining lymph nodes were also investigated for comprehensive profiling of the microenvironment. The cells of tumor-draining lymph nodes in patients with dMMR colon cancer after neoadjuvant immunotherapy were analyzed to determine their T-cell phenotype.
Results
No significant differences in presurgical clinical characteristics were detected between the dMMR and pMMR groups. However, greater disease-free survival was observed in dMMR patients than in pMMR patients (p =0.02). Approximately 52.4% of patients with dMMR treated with a whole regimen of Pd-1 blockade (dMMR+Pd-1) achieved a pathological complete response (pCR). Eight of the 42 dMMR patients experienced bowel obstruction during treatment. The single-cell transcriptome revealed enrichment of naïve-like CD8+ T cells in the TDLNs of dMMR responders. In addition, we observed that macrophages in dMMR responder TDLNs were polarized toward the M1 phenotype. The altered microenvironment was accompanied by the complete eradication of malignant cells in TDLNs upon Pd-1 blockade treatment.
Conclusions
To maintain a durable response to ICIs, TDLN preservation could be considered a potential reservoir of memory T cells to sustain ICI responses and reduce the risk of relapse and progression in dMMR+Pd-1 blockade colon cancer patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sun Yat-sen University Cancer Center.
Funding
Sun Yat-sen University Cancer Center, Chinese Society of Clinical Oncology.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
383P - Pre-treatment body mass index and neutrophil lymphocyte ratio predict 3-years progression free survival in locally advanced stage nasopharyngeal carcinoma
Presenter: Ni Putu Pusvita Dewi
Session: Poster Display
Resources:
Abstract
384P - Sequential multi-modality strategies for locally advanced betel-nuts related hypopharyngeal cancer in Taiwan
Presenter: Wei-Chen Lu
Session: Poster Display
Resources:
Abstract
385P - The prognostic factors of induction chemotherapy followed by concurrent chemoradiotherapy in patients with HPV associated with oropharyngeal cancer
Presenter: Hyun Jin Bang
Session: Poster Display
Resources:
Abstract
386P - FOLR1 stabilized beta-catenin promotes laryngeal carcinoma progression through EGFR signal
Presenter: Huawei Tuo
Session: Poster Display
Resources:
Abstract
387P - A comprehensive analysis of the oral health status, tobacco use, and cancer prevalence among the tribal communities in India
Presenter: Delfin Lovelina Francis
Session: Poster Display
Resources:
Abstract
388P - Clinicopathological correlation of P53 expression in oral cancers
Presenter: Venkata Madhavi Bellala
Session: Poster Display
Resources:
Abstract
389P - Lack of cross-resistance to erlotinib in human head and neck cancer cells with acquired resistance to cetuximab
Presenter: James A. Bonner
Session: Poster Display
Resources:
Abstract
390P - Epidemiological aspects of the development of oral cancer in the Republic of Uzbekistan
Presenter: Akhrorbek Yusupbekov
Session: Poster Display
Resources:
Abstract
391P - Lip cancer: Racial disparities, treatment modalities and long-term survival outcome in young and adults versus older age patients
Presenter: FathAlrahman Ibrahim
Session: Poster Display
Resources:
Abstract
392TiP - A prospective phase II study of individualized adjuvant therapy in patients with locally advanced hypopharyngeal cancer after neoadjuvant therapy
Presenter: Juyi Wen
Session: Poster Display
Resources:
Abstract